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Aortoiliac Stenting, Determinants of Clinical Outcome
S. Nawaz*, T. Cleveland, P. Gaines, J. Beard and P. Chan
Section of Surgery, Clinical Sciences Centre, Northern General Hospital, Herries Road, Sheffield S5 7AU, U.K.
Objectives: to determine predictors of clinical outcome in stenting aortoiliac disease.
Design: prospective/retrospective study.
Materials and methods: one hundred and forty patients (163 limbs) underwent iliac artery stenting in the period
1994–1997. Ninety-eight occlusions and 65 stenoses were treated, either with primary stenting (n=129) or after failed
angioplasty (n=34). Median follow-up 18 months (1–66). Factors analysed for their effect on outcome were: gender, age,
Fontaine stage, ABI, lesion type/length/site, primary or secondary stenting, stent type, BP, smoking, diabetes, aspirin,
cholesterol, residual gradient, overhanging and run-off.
Results: the immediate success was 95%. The primary successful clinical outcome was 90% at 12 months and 84% at
36 months; the primary-assisted successful clinical outcome was 95% at 12 months and 91% at 36 months and the
secondary successful clinical outcome was 92% at 12 months and 87% at 36 months. Adverse factors affecting outcome
were: residual pressure gradient (>10 mmHg) and no treatment with aspirin (p<0.05). Major complications occurred in
18% of patients with a re-intervention in 8%. The 30-day mortality was 5.5%.
Conclusions: stenting for aortoiliac occlusive disease has good short and long term clinical success, with low morbidity
and mortality. Factors that might improve results further are ensuring that patients are taking aspirin and any residual
pressure gradient is abolished.
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Introduction is greater and therefore the net gain may be great
enough to avoid restenosis.2,5,6
Simple balloon angioplasty of long occlusions of theSurgery for aortoiliac occlusive vascular disease is
iliac system result in poor rates of technical successsuccessful at relieving ischaemic symptoms, but less
and long term patency.5,7,8 We consider the greatestinvasive forms of treatment have the benefits of de-
potential benefit of iliac stent treatment may be increased morbidity, mortality and hospital stay.1,2 For
such situations. We therefore reviewed our last 5 years’these reasons, iliac angioplasty has become an es-
experience to evaluate an overall clinical outcome oftablished procedure.
iliac stenting and the possible determinants of thisEndovascular stents are being increasingly used to
outcome as well as to compare stent treatment oftreat aortoiliac occlusive vascular disease.3,4 However,
stenoses versus occlusions. In order to determine thethe precise indications for stent placement are not yet
true incidence of late restenosis, we have recalled adefined. In particular, the situations in which stenting,
consecutive cohort of patients, 10–14 months from theangioplasty (PTA) or surgery may be preferable have
procedure for surveillance by duplex ultrasound. Wenot been established from randomised controlled trials.
also studied the early outcome of the two major stentPrimary stenting has potential advantages over
types used in our unit, the Wallstent (Schneider)9angioplasty including better initial angiographic and
and the Memotherm stent (Angiomed/Bard).4 Specifichaemodynamic results, resistance to elastic recoil and
technical difficulties related to stent placement includefewer embolic complications. Stent placement has been
the inability to reposition stents once deployed andshown to stimulate more neo-intimal hyperplasia than
treating lesions close to the aortoiliac bifurcation. ThisPTA alone but the immediate gain in vessel diameter
can lead to overhanging of stents across the contra-
lateral iliac artery4 (Fig. 4). The long-term outcome
of overhanging stents, especially the effect on the
* Please address all correspondence to: S. Nawaz, Clinical Lecturer,
contralateral artery, is not known; therefore, we haveSection of Surgery, Clinical Sciences Centre, Northern General Hos-
pital, Herries Road, Sheffield S5 7AU, U.K. reviewed our experience for this group of patients.
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We undertook to review our experience of stenting in Successful haemodynamic outcome – An improvement by
>0.1 in the resting ABPI.the iliac system in light of our continuing randomised
controlled prospective trial comparing stenting with
Successful duplex outcome – Peak systolic velocity ratioangioplasty and surgery for iliac occlusions (STAG 1
across stent <2.5.and STAG 2).
Failure on clinical, haemodynamic or duplex criteria
was assumed if the above did not occur or an ad-
Materials and Methods ditional procedure to that segment of the artery was
performed.10 Clinical and haemodynamic outcome
Clinical assessment were analysed in the total cohort, additionally duplex
outcome analysed in the subcohort. Significant com-
From June 1992 to January 1997 we treated a total of 140 plications were defined as those requiring additional
patients with aortoiliac disease by the percutaneous intervention, prolonging the stay of the patient or
placement of metallic endovascular stents. Our in- causing a deterioration in Fontaine classification.
dications for stent placement were eccentric or diffuse
stenoses, or those with a residual pressure gradient
following conventional angioplasty, and iliac oc-
Duplex assessmentclusions. Early in our experience of treating occlusions,
stents were placed following initial balloon dilatation.
Thirty-four consecutive patients were identified asHowever, it soon became our practice to place the
having completed 12 months follow-up and they werestent without prior PTA and only postdilate the stent
then invited for duplex assessment. Scanning wasto reduce distal embolisation. All procedures were
performed by an experienced and independent son-performed in a designated angiography suite under
ographer, and the following details noted: (i) treatedlocal anaesthesia. Lesion length was determined from
segment patent; (ii) peak velocity proximal (v1) m/s;the guidewire pull-back technique. Stents were placed
(iii) peak velocity distal m/s; (iv) peak velocity in stentpercutaneously using the ipsilateral route with a 7F
(v2) m/s; (v) velocity ratio v2/v1.or 8F sheath. Systemic heparin (5000 IU) was given
A velocity ratio of >2.5 was taken to indicate sig-following arterial access, and continued for 24 h i.v.
nificant stenosis in any segment.in patients with poor run-off or following difficult
prolonged cases. The procedure was terminated when
no further improvement in the trans-stent gradient
Statisticscould be obtained. Most patients were taking aspirin
prior to treatment (more than 7 days) and continued
Results were analysed by Fisher’s exact test for non-throughout follow-up; some patients were not on as-
parametric data and by logistic regression analysispirin and nor did they take aspirin at any point after
for independent significance, using the SPSS package,treatment and this subset is discussed later. Some
statistical significance defined as p<0.05.patients were formally warfarinised (3 months); for
stents left overhanging the contralateral common iliac
origin or for ‘‘kissing stents’’.
ResultsThe preprocedural and postprocedural clinical
records, arteriograms and haemodynamic meas-
Overall outcomeurements were reviewed. The assessment of each
patient consisted of clinical examination, Fontaine cat-
One hundred and forty patients (163 limbs) wereegorisation, palpation of femoral pulses, resting ABPI
treated during a period of 66 months and included 95and where available duplex and/or angiography. Out-
men (68%) and 45 women (32%) with a mean age ofcome was recorded according to assessment at the
63.8 years (range 45–93 years). Occlusions were treatedlatest outpatient consultation.
in 98 limbs (60%) and stenoses in 65 limbs (40%). The
median lesion length was 8 cm (range 3–14 cm); 89%
of the occlusions were more than 5 cm in length. TheDefinitions of outcome
clinical presentation is detailed in Table 1. The median
preprocedural ABPI was 0.56, range 0–0.95, (thereSuccessful clinical outcome – Each limb improved by at
least one Fontaine category or if there was tissue loss, were a small number of patients with undetectable
pressure on Doppler (n=3)).by 2 categories.
Eur J Vasc Endovasc Surg Vol 17, April 1999
Stent Treatment for Aortoiliac Disease 353
Table 1. Clinical presentation and outcome at last consultation.
Fontaine Stenosis Occlusion
Pretreatment (%) Post-treatment (%) Pretreatment (%) Post-treatment (%)
I 0 (0) 40 (62) 0 (0) 55 (56)
IIA 22 (34) 15 (23) 22 (23) 14 (14)
IIB 32 (49) 5 (8) 40 (41) 9 (9)
III 5 (8) 2 (3) 10 (10) 1 (1)
IV 4 (6) 1 (2) 10 (10) 3 (3)
Table 2. Risk factors/lesion site. segment treated determines technical difficulty.14 There
were four acute stent closures successfully treated (twoStenosis (%) Occlusion (%)
thrombolysed and two treated by an aortobifemoral
Smoking 32 (49) 40 (41) graft). There were 15 late failures (at 3, 6, 6, 9, 9, 9, 12,
Hypertension 20 (31) 27 (28)
12, 12, 12, 18, 18, 20, 24, 30 months) due to restenosis,Hyperlipidaemia 5 (8) 18 (18)
Diabetes 6 (9) 9 (9) confirmed by imaging all occurring within the stent;
No aspirin treatment 9 (14) 45 (46) one was angioplastied, two stented, one treated withCommon iliac 30 (46) 48 (49)
a crossover graft, two by an aortobifemoral graft andExternal iliac 14 (22) 21 (21)
Both vessels 21 (32) 29 (30) the rest treated conservatively. All of these in-
terventions were successful; a total of 8% of the stented
limbs required re-intervention. The 30-day mortalityThe location of the diseased segment and the risk
was 5.7%. Causes of death include: 1 multi-organfactors present are detailed in Table 2. The run-off was
failure, 2 septic syndrome, 2 myocardial infarction, 2graded by the patency of the profunda femoris and
bronchial pneumonia and 1 lung cancer, and theresuperficial femoral arteries (0=occluded, 1=>50%
was only one amputation for continuing distal isch-stenosis and 2=patent). A score of 3 or less was
aemia (the stent was confirmed to be patent by duplex).designated as poor and a score of 4 was designated
The following variables were tested by univariateas good. The run-off was determined as poor in 35
analysis for their effect on outcome: gender, age, Fon-cases. There were seven additional procedures per-
taine category (claudication versus critical ischaemia),formed in the treated limb (1 iliac, 2 superficial femoral
ABPI (>0.4 versus <0.4) lesion type, lesion length,and 1 popliteal angioplasty, 2 femoropopliteal grafts
lesion site, run-off, primary stenting versus failed an-and 1 femorodistal graft). Prior angioplasty was per-
gioplasty, smoking, hypertension, diabetes mellitus,formed on 34 limbs. More than one stent was used in
hypercholesterolaemia, aspirin, stent type and residual20 limbs, giving an average of 1.4 stents used per limb.
pressure gradient. ‘‘Residual pressure gradient’’Follow-up of patients ranged from 3 months to
(>10 mmHg) and ‘‘no aspirin treatment’’ were found to60 months (median – 18 months). The median post-
be significantly associated with poor outcome (p<0.05).Fontaine score was I (see Table 1) and the median post
Further analysis by multiple regression showed thattreatment ABPI 0.91. Technical problems/com-
both these variables were independently significant.plications were encountered on 31 cases (detailed in
The residual pressure gradient was related to the bulkTable 3). All of these occurred in long and diffuse
and rigidity of the lesion which prevented the stentlesions (median length 7 cm), further providing sup-
port for the argument that the length of diseased from fully expanding.
Table 3. Technical problems and complications at 30 days.
Problem Stenosis Severity/ Occlusion Severity/
(%) outcome (%) outcome
Systemic/remote myocardial infarction 1 (0.7) 3 1 (0.7) 3
Pneumonia 1 (0.7) 3 1 (0.7) 3
Sepsis 1 (0.7) 3 1 (0.7) 3
Multi-organ failure 0 1 (0.7) 3
Lung cancer 0 1 (0.7) 3
Local/vascular thrombosis 1 (1.5) 1 3 (3) 1
Unsatisfactory haemodynamic result 6 (11) 1 23 (23) 1
Elongation 1 (1.5) 1 10 (10) 1
Embolisation 0 2 (2) 2
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Table 4. Life-table analysis of clinical outcome in total group.
Interval Limbs at risk No. failed Withdrawn Interval Cumulative SE (%)
(mo) (n=163) failure patency (%)
0 163 0 0 0 100 0 Primary
1 163 4 8 0.0245 97.5 0.9 Primary
3 151 1 0 0.0066 96.9 1.4 Primary
6 150 2 8 0.0133 95.6 1.7 Primary
9 140 3 17 0.0214 93.6 2.1 Primary
12 120 4 16 0.0333 90.5 2.5 Primary
18 100 2 8 0.0200 88.7 2.9 Primary
24 90 2 53 0.0222 86.7 3.1 Primary
30 35 1 9 0.0285 84.2 4.5 Primary
36 25 0 5 0 84.2 6.1 Primary
42 15 0 5 0 84.2 9.6 Primary
48 11 0 11 0 84.2 11.5 Primary
12 122 6 20 0.0491 95.1 2.3 Assist
24 96 4 64 0.0416 91.1 2.9 Assist
36 28 0 28 0 91.1 5.8 Assist
12 121 9 19 0.0743 92.6 2.4 Second
24 93 5 62 0.0537 87.6 3.0 Second
36 26 0 26 0 87.6 5.7 Second
was comparable (see Table 1). The preprocedural ABPI
for stenoses, range 0–0.95, mean 0.63 and for oc-
clusions, range 0–0.9, mean 0.5 (p>0.05). The location
of the diseased segment in the two groups was similar
and both groups were comparable for risk factors
(Table 2). The run-off was poor in 15 cases for stenoses
and 20 in cases of occlusions (p>0.05). Prior angioplasty
was performed on only six limbs in the occlusion
group, but in 28 limbs in the stenosis group (p<0.05),
highlighting that most occlusions are now treated by
primary stenting and half of the stenoses stented were
deemed unsuitable for balloon angioplasty alone. More
than one stent was used in eight limbs in the stenosis
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group and in 12 limbs in the occlusion group (p>0.05).
Fig. 1. ‘‘Survival curve for the whole group’’: ––– primary clinical The median post-Fontaine score was I for both sten-
outcome; ––– assisted clinical outcome; · · · · · · secondary clinical oses and occlusions (see Table 1), median post-treatment
outcome.
ABPI was 0.89 for stenoses and 0.93 for occlusions.
Technical problems/complications were encountered onKaplan–Meier life calculations for predicted primary,
five occasions in the stenoses group but 26 cases in theassisted and secondary successful clinical outcomes are
occlusion group (detailed in Table 3); in particular failuredetailed in Table 4 and Fig. 1. The significant de-
to place stent was encountered on two (3%) occasionsterminants of clinical outcome, namely residual pressure
in the stenoses group and six (6%) occasions in thegradient and aspirin treatment, their effect on outcome
occlusion group. There was one acute closure in theis detailed in Tables 5–8 and in Figs 2 and 3.
stenoses group successfully thrombolysed. There were
three acute closures in the occlusion group (one throm-
bolysed and two treated by an aortobifemoral graft).
There were six late failures in the stenoses group (at 6,Stenoses vs. occlusions
9, 12, 12 and 24 months); one was angioplastied, one
stented, one treated with a crossover graft, and the restOcclusions were treated in 98 limbs (60%) and stenoses
treated conservatively. There were nine late failures inin 65 limbs (40%). The median lesion length was 8 cm
the occlusion group, (at 3, 6, 9, 9, 12, 12, 18, 18 and 30(range 3–14 cm); 89% of the occlusions were more
months), two were treated with an aortobifemoral graft,than 5 cm in length. The age range of patients with
one stented and the rest treated conservatively. The 30-occlusions was 39–91 years (median=62) and of
day mortality for the stenoses group was 2.1% and 3.6%patients with stenoses 42–83 years (median=63). The
clinical presentation for both stenoses and occlusions for the occlusion group.
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Table 5. Life-table analysis of clinical outcome for no aspirin.
Interval Limbs at risk No. failed Withdrawn Interval Cumulative SE (%)
(mo) (n=90) failure patency (%)
0 90 0 0 0 100 0
1 90 3 5 0.0333 96.7 1.8
3 82 1 1 0.0121 95.5 2.3
6 84 2 6 0.0238 93.2 2.7
9 76 3 2 0.0394 89.5 3.3
12 71 3 6 0.0422 85.7 3.8
18 62 1 9 0.0161 84.3 4.4
24 52 2 27 0.0384 81.1 4.9
36 23 1 16 0.0434 77.6 7.4
48 6 0 6 0 77.6 14.6
Table 6. Life-table analysis of clinical outcome for on aspirin.
Interval Limbs at risk No. failed Withdrawn Interval Cumulative SE (%)
(mo) (n=75) failure patency (%)
0 75 0 0 0 100 0
1 75 1 3 0.0133 98.7 1.2
3 71 0 6 0 98.7 1.4
6 65 0 4 0 98.7 1.8
9 61 0 6 0 98.7 2.0
12 55 1 5 0.0181 96.9 2.3
18 49 1 2 0.0204 94.9 2.5
24 46 0 24 0 94.9 2.6
36 22 0 18 0 94.9 4.6
48 4 0 4 0 94.8 10.7
Table 7. Life-table analysis of clinical outcome for residual gradient.
Interval Limbs at risk No. failed Withdrawn Interval Cumulative SE (%)
(mo) (n=29) failure patency (%)
0 29 0 0 0 100 0
1 29 2 1 0.0689 93.1 4.1
3 26 1 1 0.0384 89.5 4.5
6 24 1 1 0.0416 85.8 6.1
9 22 1 1 0.0454 81.9 7.2
12 20 1 2 0.0500 77.8 7.9
18 17 2 3 0.1176 68.7 9.4
24 12 1 7 0.0833 62.9 11.1
36 4 0 4 0 62.9 19.2
Table 8. Life-table analysis of clinical outcome for no gradient.
Interval Limbs at risk No. failed Withdrawn Interval Cumulative SE (%)
(mo) (n=134) failure patency (%)
0 134 0 0 0 100 0
1 134 2 7 0.0149 98.5 0.7
3 125 0 4 0 98.5 1.2
6 121 1 16 0.0082 97.7 1.5
9 104 2 20 0.0192 95.8 2.1
12 82 3 18 0.0365 92.3 2.6
18 61 0 8 0 92.3 3.2
24 53 1 28 0.0188 90.6 4.4
36 24 1 16 0.0416 86.8 6.2
48 7 0 7 0 86.8 11.5
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Fig. 2. ‘‘Survival curve for aspirin treatment’’: ––– on aspirin; –––
no aspirin.
Fig. 4. ‘‘Showing a stent in the left common iliac artery overhanging
the right common iliac artery origin’’.
ABI was 0.45 and 0.62 respectively for Wallstent and
Memotherm stent. The run-off was similar in both
groups and the sites of the lesion were similarly dis-
tributed in the two groups with a median length of
7 cm treated by both stents. The median stent length
used was 77 mm for the Wallstent group and 85 mm
for the Memotherm with the same median diameter.
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Both groups were followed for a median length ofFig. 3. ‘‘Survival curve for residual pressure gradient’’: ––– residual
14 months, the median post-treatment ABI was 0.9pressure gradient; ––– no residual pressure gradient.
and 1.03 with the change in ABI post treatment of
0.4 and 0.36 for the Wallstent and the MemothermKaplan–Meier life calculation for predicted primary
respectively.clinical outcome for the occlusion group at 12 months
The two groups were well matched and had similarwas 91%, at 24 months 88% and at 36 months 84%; the
outcomes as determined by Fontaine score and ABIs.secondary clinical outcome was 92%, 90% and 90%,
There were similar technical problems and com-respectively. For the stenoses group the primary clinical
plications with both stents, none of the amputationsoutcome was 92%, 90% and 88%, and the secondary
or deaths were procedure-related. The 30-day clinicalclinical outcome was 94%, 92% and 90%, respectively.
success was 98.5% and 95.6%, respectively, for Wall-No significant difference in the clinical outcome was
stent and Memotherm stent.seen between the two groups.
Although there was a slight increase in the 30-day
occlusion rate for the Memotherm stent (p>0.05), the
Wallstent had a slightly higher late failure (p>0.05)
Memotherm vs. Wallstent and therefore the overall clinical outcome to 18 months
was similar.A total of 140 patients (160 limbs) had 175 stents
placed in their iliac arteries. 67 limbs were treated
with Wallstent and 69 with Memotherm stent. In the
Wallstent group 28% had stenoses, 72% occlusions and Overhanging stents
in the Memotherm group 46% were stenoses and 54%
occlusions. The median age of the patients and risk Ten patients were identified from a total of 140 where
the stent was overhanging the contralateral iliac arteryfactors were comparable in the two groups. The pre-
and post-treatment (last consultation) Fontaine score origin (Fig. 4). This group included eight males and
two females with a mean age of 60.3 years (range 48–82was similar for both groups. The median pretreatment
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years). Five patients presented with mild claudication, common femoral artery angioplasty, one popliteal ar-
tery angioplasty and one femoropopliteal graft).four with severe claudication and one with rest pain;
the mean pre-ABI was 0.5 (range 0.1–0.88). Nine lesions There were five restenoses and two reocclusions
that were identified by scanning (increased velocitywere occlusions with a mean length of 6.2 cm and one
stenosis; eight lesions were confined to the common ratios across stent in all cases) giving a stent failure
rate of 17.5% on an intention to scan basis; all of theseiliac and two extended to the external iliac. Wallstent
and Memotherm stents were used on five occasions occurred in a primary occlusive lesion (p<0.05).
each. The aorta and contralateral iliac origin was free
of significant disease in all cases.
The degree of overhanging was determined by re-
Discussionviewing the original films, the median length was
5 mm (range 3–15 mm). Eight patients were hep-
Despite the relatively successful use of balloon an-arinised for 24 hours and three were further anti-
gioplasty for the treatment of aortoiliac disease, sig-coagulated with warfarin for 6 months. Follow-up was
nificant problems have been encountered. Theyavailable for nine patients (one lost to follow-up) with
include late restenosis, dissection, difficulty in treatinga median follow-up of 10 months (range 1–60 months).
occlusions and the potential danger of distal em-Eight patients were symptom-free at last follow-up
bolisation.2,4,5,8 It was thought that the use of metallicand one had mild claudication. The median post-
stents as internal scaffolds would negate these prob-treatment ABI was 1.01 (range 0.82–1.28). Two stents
lems.4 Few studies exist to answer these questionsfailed (20%), both on the ipsilateral side; one at 9
properly, hence the need for a randomised controlledmonths and the other at 11 months. The failed stents
trial.were treated, one by further stent placement and the
Palmaz et al. have reported a series on 486 stentedother by a crossover graft. Both patients were hep-
patients: the clinical patency was 90.9% at 1 year, 84.1%arinised for 24 hours and warfarinised for 6 months.
at 2 years and 68.6% at 43 months.11 A Wallstent trialNo complication has occurred to the contralateral side.
reported that on 163 limbs the primary patency by
clinical means was 81% at 1 year and 71% at 2 years.9
In our series we treated 161 limbs by percutaneous
stent placement and we achieved a 95% technicalDuplex outcome
success and a primary clinical outcome of 90% and
84% at 12 months and 42 months respectively; thisThirty-one patients were examined and three did not
attend (one was too sick to attend, two refused); six compares well with the above large series. A meta-
analysis comparing PTA with stenting suggests thatpatients had bilateral stents giving the total number
of limbs treated as 40. the addition of a stent improves immediate and long-
term patency7 as well as the intra-arterial pressureThere were seven women and 27 men with a median
age of 61 years (range 43–83 years). Thirty limbs gradient.12 Recently selective iliac stenting has been
recommended from the Dutch trial,13 which comparedpresented with claudication and ten with rest pain,
with a median ABI of 0.48 (range 0.1–0.94). A stenotic primary stenting versus angioplasty and selective
stenting in these cases with a residual gradient oflesion was treated in ten cases and an occluded lesion
in 30 cases with a median length of 7 cm (range 5–7 cm). >10 mmHg. There was a similar 2-year patency of 74%
and 75%, respectively, for the two groups; but thisThe lesion was confined to the common iliac in 22
cases, and involved the external iliac only in all others. study excluded patients with diffuse disease and long
iliac occlusions (>5 cm). Murphy and Cikrit et al. havePatient risk factors were similar to the total group.
Wallstent was used in 15 limbs, Memotherm in 20 reported on the use of Palmaz stents and report an
overall 86.2% patency at 4 years. However, with iliaclimbs and another stent was used on other occasions.
The median stent length was 8 cm and the median occlusions and diffuse iliac disease this falls to only a
78% patency at 1 year, down to 53% at 2 years.11,14diameter was 8 mm. Five sites were treated with more
than one stent. The run-off was good in 22 legs and There are few studies specifically comparing sten-
oses with occlusions but the study by Murphy,9 andpoor in 18 legs.
Following stent placement there was a residual gra- others15 which concentrate on disease distribution con-
clude that the patency rates for stenosis and occlusionsdient (>10 mmHg) in 11 cases and one case of acute
thrombosis (at 3 weeks) successfully treated by throm- are similar. Diffuse disease produced the worst results;
this conclusion is also reached by Dyet et al.16 Vorwerkbectomy. In addition there were three further pro-
cedures performed at other anatomical sites (one and his colleagues6 also report good primary and
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secondary patency rates for occlusions, as does Blum.17 threat to the contralateral side. The primary clinical
outcome of the ipsilateral side at 12 months was onlyHowever, none of these studies compared stenoses
80% as compared with 90% for the overall group andwith occlusions.
all failures occurred late. This would suggest thatWe have looked at the outcome of limbs with sten-
overhanging of the stents leads to accelerated neo-oses or occlusions. The majority of stenoses were either
intimal hyperplasia or an alternative explanationcomplex or diffuse as highlighted by the number of
would be that these stents have a smaller radial forcefailed angioplasties and a median length of 7 cm, but
and hence smaller net luminal gain, or that highboth groups are comparable in their demographic data,
deforming forces are at the iliac ostium where therisk factors and clinical presentation. The median pre-
stents are at their weakest.ABI and run-off was slightly worse in the occlusion
There is difficulty in comparing the various pub-group but there was no statistical difference (p>0.05).
lished studies on stents due to different protocols,Lesion site characteristics were not significantly dif-
differing assessment criteria and follow-up. The ma-ferent and the stent type used was comparable in the
jority of these studies report clinical criteria as a meanstwo groups. Occlusions are said to be technically more
of assessment, but this is subjective and does notdemanding and we confirmed this finding. There was
directly assess stent patency. Duplex ultrasound is safea greater rate of residual gradient and overhanging
and comparable to angiography in assessment of thethe contralateral iliac artery in the occlusion group
iliac system.18 We therefore followed a cohort of(p<0.05). Comparing the two groups for immediate
patients with duplex to assess 1-year patency. Ourclinical success as determined by restoration of the
consecutive cohort resembles the overall group closelyfemoral pulse, Fontaine score and ABIs at last follow-
in severity of disease and risk factors, although thereup produced no significant difference (p>0.05). Al-
were a greater number of occlusions. The success ratethough there were a greater number of late stent
at 12 months was 82.5%, and is superior to publishedfailures (restenosis and reocclusion) in the occlusion
data on angioplasty for occlusions of 79%,10 and alsogroup, this did not reach statistical significance
in case of angioplasty for both stenoses and occlusions(p>0.05). However, there did appear to be a worrying
(60% and 79%),6 and compares well with stenting forincidence of asymptomatic late restenosis in our du-
occlusions (87% and 85%).14,20plex-scanned cohort, which might have been masked
The clinical success for the whole group at 1 yearby clinical assessment in the whole patient group (see
was 90% as compared with the duplex determinedbelow).
success rate of 82.5% in the cohort, confirming existingOur data confirmed that patients not taking aspirin
knowledge that clinical follow-up alone is not entirelywere at risk for stent failure (p<0.05); residual gradient reliable. This high rate of asymptomatic restenosis
(>10 mmHg) was also significant (p<0.05). Making re- would seem to suggest that continuing late restenosis
commendations on these risk factors for patient se- is occurring and would warrant duplex surveillance
lection is difficult, since most studies on this subject to identify and treat early any haemodynamically
conflict in their findings; however, our search failed significant but asymptomatic restenotic lesions by
to find any other study looking at the effect of aspirin either balloon angioplasty or atherectomy. The effect
on stent outcome. We found no significant difference of this on later outcome is as yet unknown (as is also
in the performance of the 2 self-expanding stents. the case for surveillance programmes for infrainguinal
The potential problem of overhanging to the contra- grafts). An alternative reason for this difference may
lateral side was initially tackled at this centre by using be due to poor outcome in a group of patients lost to
the technique of ‘‘kissing’’ stents where two stents are follow-up, or that results in recently stented patients
placed along each other in both the common iliacs, may not be durable, and skew the results towards less
together with heparinisation and warfarinisation. Five favourable outcome over longer follow-up periods.
patients were treated in this manner; with one ex-
ception all the other contralateral iliacs were normal.
A total of two (n=5) stents failed (40%) on the ipsi-
lateral side, but to date the contralateral side remains Conclusions
patent. With such a high failure this technique was
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